Wall Street analyst price targets, ratings consensus & upside potential
Last 12 months price action with 12-month analyst target path
As of March 3, 2026, National HealthCare Corporation (NHC) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $2.54B.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, NHC trades at a trailing P/E of 21.3x and forward P/E of 20.5x. The forward PEG ratio of 0.89 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow +23.3% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $167.82, with bear and bull scenarios of $83.63 and $294.08 respectively. Model confidence stands at 63/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how NHC stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for NHC is $N/A, close to the current price of $163.5 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
NHC has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
NHC trades at a forward P/E of 20.5144x, representing a moderate valuation. With analysts targeting $N/A (N/A% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $N/A for NHC, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $294 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NHC is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NHC stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A". Our proprietary valuation model produces a base case fair value of $168, with bear/bull scenarios of $84/$294.
Our quantitative valuation model calculates NHC's fair value at $168 (base case), with a bear case of $84 and bull case of $294. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 63/100.
NHC trades at a forward P/E ratio of 20.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 21.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
NHC appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NHC analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $84-$294 range provides an independent fundamental perspective.